Core Viewpoint - Quantum BioPharma Ltd. has announced the establishment of October 27, 2025, as the record date for the distribution of contingent value rights (CVRs) to holders of its Class B Subordinate Voting Shares, linking potential future recoveries from ongoing litigation directly to shareholders [1][3]. Group 1: CVR Distribution Details - Each CVR will allow holders to receive a pro rata portion of a minimum of 10% and up to 50% of the net proceeds recovered from the Company's legal action against CIBC World Markets, RBC Dominion Securities, and others, which alleges stock price manipulation and seeks damages exceeding USD $700 million [2]. - Payments under the CVRs will only occur if the Company receives net proceeds from the litigation following a settlement or a final, non-appealable judgment, referred to as "Qualifying Net Proceeds" [2][4]. - The distribution date for the CVRs is currently undetermined and contingent upon the Company receiving Qualifying Net Proceeds from the litigation [5]. Group 2: Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with its lead compound, Lucid-MS, aimed at preventing and reversing myelin degradation associated with multiple sclerosis [6]. - The Company retains a 20.10% ownership stake in Unbuzzd Wellness Inc., which is involved in the development of the unbuzzd™ product, and is entitled to royalty payments of 7% of sales until total payments reach $250 million, after which the royalty rate will drop to 3% [6]. - Quantum BioPharma also maintains a portfolio of strategic investments through its subsidiary, FSD Strategic Investments Inc., which includes loans secured by residential or commercial property [6].